Loading...

Pixium Vision SA

ALPIX.PAEURONEXT
HealthcareMedical - Instruments & Supplies
0.38
-0.04(-10.17%)

Pixium Vision SA (ALPIX.PA) Stock Overview

Explore Pixium Vision SA’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for ALPIX.PAStats details for ALPIX.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALPIX.PAAnalyst Recommendations details for ALPIX.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

CEO

Mr. Lloyd Diamond

Employees

40

Headquarters

74 rue du Faubourg Saint-Antoine, Paris

Founded

2014

Frequently Asked Questions